Abstracts tagged "dermatomyositis"

Abstract Number: 2577 • ACR Convergence 2023
Frequency of Atherosclerotic Cardiovascular Disease Following a Diagnosis of Idiopathic Inflammatory Myopathy: Data from a Large National Registry
Astia Allenzara¹, Carolina Alvarez², Amanda Nelson³ and Galen Foulke⁴, ¹University of North Carolina, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Penn State MS Hershey Medical Center, Hershey, PA
Background/Purpose: Idiopathic inflammatory myopathies confer an increased risk of morbidity from cardiovascular disease. Prior work has noted more than double risk of cardiovascular events for…
Abstract Number: 0023 • ACR Convergence 2023
Proteomic Analysis of Plasma-derived Extracellular Vesicles Renders Glutathione Peroxidase 3 a Biomarker for Dermatomyositis
Avital Baniel¹, Mariko Ogawa-Momohara², Muhammad Bashir³, Rachita Pandya¹, Julianne Kleitsch¹, Felix Chin⁴, Ming-Lin Liu¹ and Victoria P. Werth⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵University of Pennsylvania, Wynnewood, PA
Background/Purpose: Extracellular vesicles (EVs) have been implicated in autoimmune disease pathogenesis. Plasma-derived DNA containing EVs have been shown to induce STING-mediated proinflammatory responses in dermatomyositis…
Abstract Number: 1161 • ACR Convergence 2023
Proteasome Inhibitor Repurposed for Dermatomyositis: Results of a Drug Repurposing Analysis Based on the Transcriptomic Signature of Patients’ Perifascicular Fibers Validated in Pre-clinical Models
Léa Debrut¹, Margherita Giannini², Céline Keime¹, Daniela Rovito¹, Béatrice Lannes³, Anne-Laure Charles⁴, Daniel Metzger¹, Bernard Geny⁵, Gilles Laverny¹ and Alain Meyer⁶, ¹Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch, France, ²Nouvel Hopital Civil, Strasbourg, Strasbourg, France, ³Hôpital de Hautepierre - Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁴UR3072, Centre de Recherche en Biomédecine de Strasbourg (CRBS), Strasbourg, France, ⁵Nouvel Hôpital Civil, Strasbourg, France, ⁶Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Background/Purpose: Dermatomyositis (DM) is an autoimmune myopathy responsible for muscle weakness associated with decreased quality of life and increased mortality. DM muscular histology is characterized…
Abstract Number: 1657 • ACR Convergence 2023
Mapping the Network of Coordinated Immune Dysregulation in Juvenile Dermatomyositis at Single-cell Resolution
Gabrielle Rabadam¹, Camilla Wibrand², Emily Flynn¹, George Hartoularos¹, Yang Sun¹, Susan Kim³, Chun Jimmie Ye¹, Zev Gartner¹, Marina Sirota⁴ and Jessica Neely¹, ¹University of California San Francisco, San Francisco, CA, ²Aarhus University, Aarhus, Denmark, and University of California San Francisco, San Francisco, CA, ³UCSF Benioff Children's Hospital, San Francisco, CA, ⁴Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA
Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare multisystem autoimmune condition that involves complex immune responses in both innate and adaptive compartments. Currently, we have a…
Abstract Number: 2579 • ACR Convergence 2023
Validation of PROMIS in Adult and Pediatric Patients with Idiopathic Inflammatory Myopathies
Emma Austenfeld¹, Sara Sabbagh¹, Melodee Liegl¹, Ke Yan¹, Julie Fuller², Kelly Rouster-Stevens³, Lisa Rider⁴ and Adam Schiffenbauer⁴, ¹Medical College of Wisconsin, Wauwatosa, WI, ²UT Southwestern and Scottish Rite for Children, Dallas, TX, ³Emory University/Children's Healthcare of Atlanta, Norcross, GA, ⁴NIEHS, NIH, Bethesda, MD
Background/Purpose: This study aimed to validate the Patient Reported Outcome Measurement Information System (PROMIS) tools in patients with adult and juvenile idiopathic inflammatory myopathies (IIM/JIIM)…
Abstract Number: 0085 • ACR Convergence 2023
Fibroblasts Promote Upregulation of Cannabinoid Type 2 Receptor on Inflammatory Cells in Dermatomyositis
DeAnna Diaz¹, Muhammad Bashir¹, Rohan Dhiman², Avital Baniel¹, Julianne Kleitsch¹, Rachita Pandya¹, Meena Sharma¹, Thomas Vazquez¹, Ming-Lin Liu², Mariko Momohara² and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania and Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: Dermatomyositis (DM) is a chronic, systemic autoimmune disease affecting the skin, muscle, and lungs. The activation of CB2R has been shown to reduce several,…
Abstract Number: 1163 • ACR Convergence 2023
Anti-melanoma Differentiation Associated Gene 5 (Anti-MDA5) Antibody Dermatomyositis: Clinical Features and Outcome in a Racially Diverse Patient Cohort
Sai Koyoda¹, Dawn Wahezi², Xianhong Xie³, Anand Kumthekar⁴, Clement Tagoe³ and Bibi Ayesha⁵, ¹Essen Medical Center, Rahway, NJ, ²Children's Hospital at Montefiore, New Rochelle, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁵Montefiore Medical Center, Bronx, NY
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody dermatomyositis typically expresses rapidly progressing interstitial lung disease (RP-ILD) and ulcerative skin lesions, with or without muscle involvement.…
Abstract Number: 1709 • ACR Convergence 2023
Tape Stripping Expression Signatures Identify Biologically Unique Juvenile Dermatomyositis Patient Subgroup Characterized by Increased Mitochondrial Dysfunction
Jessica Turnier, Celine Berthier, Sarah Vandenbergen, Christine Goudsmit, Madison McClune, Johann E. Gudjonsson, Lam Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation in juvenile dermatomyositis (JDM) can signal disease onset or flare and prevent complete disease remission. The study of cutaneous expression signatures holds…
Abstract Number: 0126 • ACR Convergence 2023
Epidemiology and Retrospective Case-Control Analysis of IIM in the US Veteran Population
Vladimir Liarski, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic Inflammatory Myopathy (IIM) - comprising polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM) - is rare and difficult to study. We sought…
Abstract Number: 1164 • ACR Convergence 2023
Can We Differentiate Patients with Dysferlinopathies and Inflammatory Myopathies by Muscle Ultrasound? A Discriminant Analysis Study
Carina Soto-Fajardo¹, Sinthia Solorzano Flores¹, Abish Angeles-Acuña¹, Fabian Carranza Enriquez¹, Rosa-Elena Escobar-Cedillo², Saul Renan-Leon², Karina Arias Callejas³, Alejandra Enriquez-Luna², Graciliano Ramon-Diaz² and Carlos Pineda², ¹Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, ²Instituto Nacional de Rehabilitacion, Mexico City, Mexico, ³Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico
Background/Purpose: Immune-mediated myopathies (IMM) are a heterogeneous group of diseases characterized by inflammation and muscle weakness; among their differential diagnoses are the dysferlinopathies, which are…
Abstract Number: 1814 • ACR Convergence 2023
Silica and Other Exposures from Jobs and Hobbies Are Associated with Myositis Phenotype in a National Myositis Registry
Christine Parks¹, Jesse Wilkerson², Payam Noroozi Farhad³, Nastaran Bayat⁴, Adam Schiffenbauer⁵, Hermine Brunner⁶, Robert Goldberg⁷, Frederick Miller⁸ and Lisa Rider⁵, ¹Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, ²NIEHS/NIH, Durham, NC, ³Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁴Social Scientific Systems, DLH Holdings Corp, Silver Spring, MD, ⁵NIEHS, NIH, Bethesda, MD, ⁶Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ⁷Myositis Foundation, Alexandria, VA, ⁸NIH, NIEHS, Chapel Hill, NC
Background/Purpose: Growing evidence suggests that environmental factors may contribute to disease phenotype among patients diagnosed with the idiopathic inflammatory myopathies (IIM), dermatomyositis (DM), polymyositis (PM),…
Abstract Number: 0285 • ACR Convergence 2023
Patient Reported Physical Function, Mental Health, and Treatment Patterns in Dermatomyositis
Lisa Christopher-Stine¹, Julie Paik¹, Brendan M. Johnson², Taryn Smith², Jolie Feldman² and Paul N. Mudd Jr.², ¹Johns Hopkins University, Baltimore, MD, ²Priovant Therapeutics, Durham, NC
Background/Purpose: Dermatomyositis (DM) is a rare, debilitating, idiopathic inflammatory myopathy characterized by painful, itchy skin rash and proximal muscle weakness that can significantly impact daily…
Abstract Number: 1165 • ACR Convergence 2023
Long-term Changes in Lung Function in Melanoma Differentiation-associated Protein 5 (MDA5) Antibody Positive Dermatomyositis Patients: Experience of a Single Center Longitudinal Cohort in North America
Jenice Cheah¹, Sangmee Bae², Tiffany De Leon², Yuna Lee¹ and Christina Charles-Schoeman³, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA Rheumatology, Los Angeles, CA, ³UCLA Medical Center, Santa Monica, CA
Background/Purpose: Interstitial lung disease (ILD) associated with antibodies to melanoma differentiation-associated protein 5 (MDA5 ab) in patients with dermatomyositis (DM) has been associated with a…
Abstract Number: 1946 • ACR Convergence 2023
Zetomipzomib Demonstrates Favorable Long-term Safety and Tolerability Profile Without Signs of Immunosuppression: Results from the PRESIDIO Study and Its Open-label Extension Study in Patients with Dermatomyositis and Polymyositis
Rohit Aggarwal¹, Namita Goyal², Diana Lam³, Allen Ng³, Richard Leff⁴, Kathryn Ray³, Eunmi Park³ and Noreen Henig³, ¹University of Pittsburgh, Pittsburgh, PA, ²UCI Health, Orange, CA, ³Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, Chadds Ford, PA
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are chronic autoimmune diseases characterized by muscle inflammation and weakness. In a collagen-induced myositis mouse model, immunoproteasome inhibition has…
Abstract Number: 0289 • ACR Convergence 2023
Markers of Endothelial Damage Are Elevated in Patients with Dermatomyositis Associated Interstitial Lung Disease and Associated with Low Paraoxonase-1 Activity
Sangmee Bae¹, Ani Shahbazian¹, Jennifer Wang², Tiffany De Leon¹, Yuna Lee¹, srinivasa Reddy³ and Christina Charles-Schoeman⁴, ¹UCLA Rheumatology, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA, ³UCLA Department of Molecular and Medical Pharmacology, Los Angeles, CA, ⁴UCLA Medical Center, Santa Monica, CA
Background/Purpose: Damage to the vascular endothelium is implicated in the pathogenesis of idiopathic inflammatory myopathies (IIM) and its associated interstitial lung disease (ILD), with microvascular…

« Previous Page
1
…
4
5
6
7
8
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].